NASDAQ:UROVUrovant Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Urovant Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.50 0.00 (0.00 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$10.23Now: $10.50▼$10.7250-Day Range$8.27MA: $10.11▼$11.8052-Week Range$6.55Now: $10.50▼$15.98Volume94,500 shsAverage Volume72,232 shsMarket Capitalization$323.39 millionP/E RatioN/ADividend YieldN/ABeta1.45 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingUrovant Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Urovant Sciences has a potential upside of 166.7% from its current price of $10.50.Amount of Analyst CoverageUrovant Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesUrovant Sciences has received 70 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUrovant Sciences has received 96 “underperform” votes. (Add your “underperform” vote.)Community SentimentUrovant Sciences has received 57.83% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Urovant Sciences and other stocks. Vote “Outperform” if you believe UROV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UROV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUrovant Sciences does not currently pay a dividend.Dividend GrowthUrovant Sciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Urovant Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.62% of the stock of Urovant Sciences is held by insiders.Percentage Held by InstitutionsOnly 23.81% of the stock of Urovant Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Urovant Sciences are expected to grow in the coming year, from ($6.88) to ($5.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Urovant Sciences is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Urovant Sciences is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.25 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UROV Previous Symbol CUSIPN/A CIKN/A Webwww.urovant.com Phone44-20-7400-3347Debt Debt-to-Equity RatioN/A Current Ratio1.89 Quick Ratio1.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.90) per share Price / Book-5.53Profitability EPS (Most Recent Fiscal Year)($4.71) Net Income$-146,740,000.00 Net MarginsN/A Return on Equity-6,363.46% Return on Assets-155.51%Miscellaneous Employees17 Outstanding Shares30,799,000Market Cap$323.39 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:UROV Rates by TradingView Receive UROV News and Ratings via Email Sign-up to receive the latest news and ratings for UROV and its competitors with MarketBeat's FREE daily newsletter. Urovant Sciences (NASDAQ:UROV) Frequently Asked Questions How has Urovant Sciences' stock been impacted by COVID-19 (Coronavirus)? Urovant Sciences' stock was trading at $11.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, UROV shares have decreased by 7.7% and is now trading at $10.50. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Urovant Sciences? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urovant Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Urovant Sciences. When is Urovant Sciences' next earnings date? Urovant Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Urovant Sciences. How were Urovant Sciences' earnings last quarter? Urovant Sciences Ltd (NASDAQ:UROV) released its quarterly earnings results on Thursday, June, 18th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.25) by $0.43. View Urovant Sciences' earnings history. What price target have analysts set for UROV? 1 analysts have issued 1 year price objectives for Urovant Sciences' shares. Their forecasts range from $28.00 to $28.00. On average, they anticipate Urovant Sciences' stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 166.7% from the stock's current price. View analysts' price targets for Urovant Sciences. Has Urovant Sciences been receiving favorable news coverage? Headlines about UROV stock have been trending somewhat negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Urovant Sciences earned a news impact score of -1.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Urovant Sciences. Who are some of Urovant Sciences' key competitors? Some companies that are related to Urovant Sciences include Rocket Pharmaceuticals (RCKT), Supernus Pharmaceuticals (SUPN), I-Mab (ARQT), Constellation Pharmaceuticals (CNST), Athenex (ATNX), Aimmune Therapeutics (AIMT), Arcus Biosciences (RCUS), BioXcel Therapeutics (BTAI), Phibro Animal Health (PAHC), Amphastar Pharmaceuticals (AMPH), Enanta Pharmaceuticals (ENTA), Legend Biotech (PLRX), Rhythm Pharmaceuticals (RYTM), Nabriva Therapeutics (NBRV) and Arcturus Therapeutics (ARCT). View all competitors. What other stocks do shareholders of Urovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Urovant Sciences investors own include Opko Health (OPK), Agile Therapeutics (AGRX), CytomX Therapeutics (CTMX), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Anavex Life Sciences (AVXL), Corbus Pharmaceuticals (CRBP), Flexion Therapeutics (FLXN), Gilead Sciences (GILD) and Myovant Sciences (MYOV). Who are Urovant Sciences' key executives? Urovant Sciences' management team includes the following people: Mr. Keith A. Katkin, CEO & Director (Age 48)Ms. Christine G. Ocampo, Chief Accounting Officer and Principal Financial & Accounting Officer (Age 47)Mr. Michael E. McFadden, Chief Commercial Officer of USI (Age 52)Dr. David Hovland, Sr. VP of Global Regulatory AffairsMs. Nori Ebersole, Sr. VP & Chief HR Officer of USI (Age 56) When did Urovant Sciences IPO? (UROV) raised $150 million in an IPO on Thursday, September 27th 2018. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO. What is Urovant Sciences' stock symbol? Urovant Sciences trades on the NASDAQ under the ticker symbol "UROV." How do I buy shares of Urovant Sciences? Shares of UROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Urovant Sciences' stock price today? One share of UROV stock can currently be purchased for approximately $10.50. How big of a company is Urovant Sciences? Urovant Sciences has a market capitalization of $323.39 million. The company earns $-146,740,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Urovant Sciences employs 17 workers across the globe. What is Urovant Sciences' official website? The official website for Urovant Sciences is www.urovant.com. How can I contact Urovant Sciences? Urovant Sciences' mailing address is 11-12 ST. JAMES S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected] This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
